在接受抗IL-17药物的牛皮患者中患多发性硬化症的风险:基于病例的综述
Sotirios G Tsiogkas1, Vaia Tsimourtou2, Kleoniki Chaidaki1
1Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
The Journal of dermatology
|February 12, 2024
概括
治疗牛皮的ixekizumab等生物药物很少引起严重的副作用. 然而,这份报告详细介绍了一例发生在抗白蛋白-17治疗后的多发性硬化症 (MS),促使对类似的罕见神经事件进行审查.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 神经免疫学 神经免疫学
- 药物监督 药物监督 药物监督
背景情况:
- 生物疗法,特别是抗-17 (IL-17) 药物,对于牛皮是有效的.
- 这些治疗方法通常具有良好的安全性,但很少出现严重的不良事件.
- 有关潜在的神经系统不良事件,包括脱髓化,存在担忧.
研究的目的:
- 报告患有新发多发性硬化症 (MS) 的病例,该病例发生在接受抗IL-17药物ixekizumab治疗的患者中.
- 审查关于在患有牛皮和脱髓化疾病的患者中使用抗IL-17药物的现有文献.
- 评估抗IL-17治疗与中枢神经系统炎症事件之间的潜在关联.
主要方法:
- 在ixekizumab治疗后发生多发性硬化症的患者的病例报告介绍.
- 对病例报告和涉及抗IL-17药物 (ixekizumab,secukinumab) 和脱髓化的研究的系统文献综述.
- 对有关皮肤和神经症状的临床结果的分析.
主要成果:
- 一名患者在开始治疗牛皮的ixekizumab治疗8个月后患上多发性硬化症.
- 审查发现了八个相关病例报告;大多数都显示了用抗IL-17药物充分控制皮肤和神经症状.
- 罕见的MS恶化 (secukinumab) 和脑膜炎 (ixekizumab) 病例也被发现.
结论:
- 虽然抗IL-17生物药物通常对牛皮是安全的,但罕见的MS等脱髓化事件需要考虑.
- 抗IL-17药物和中枢神经系统炎症之间的因果关系尚未被证明,但应该考虑这种可能性.
- 临床医生应对接受抗IL-17治疗牛皮的患者的神经症状保持警.
相关概念视频
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
164
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
164